Alvotech (ALVO)
Alvotech develops and manufactures biosimilar medicines, sold through pharmaceutical partners to patients worldwide. It last closed at $4.37 on Nov 17, down 0.79% on the day. The average 12-month price target from 3 analysts is $8.00 (+83.1% from the last close), with a high of $9.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From ALVO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ALVO in the past 90 days. The average target is $8.00, with a high of $9.00 and a low of $7.00, compared with the last close of $4.37.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Jefferies | Initiated | Buy | $9 |
| Sep 16 | Barclays | Upgrade | Buy | $8 |
| Aug 24 | B of A Securities | Initiated | Buy | $7 |
Technical Analysis
The stock is 7% below its 20 day and 19% below its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $4.36, and the nearest resistance the Pivot R1 at $4.49.
| RSI (14) | 40.56 | Middle of its range | Neutral |
| MACD | -0.19 | Below its signal line | Bearish |
| Stochastic | 20.9 | Middle of its range | Neutral |
| ADX (14) | 17.0 | No clear trend | |
| Williams %R | -73.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -132.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −3.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.31 | Typical daily range, 7.1% of price |
| RSI (14) | 47.08 | Middle of its range | Neutral |
| MACD | 0.10 | Below its signal line | Bearish |
| Stochastic | 27.2 | Middle of its range | Neutral |
| ADX (14) | 21.9 | Weak trend | |
| Williams %R | -77.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -25.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −17.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.65 | Typical daily range, 15.0% of price |
What happened before
See how ALVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in ALVO in the last 90 days.
ALVO Institutional Ownership
Full report →- ▲50 buying vs 23 selling
- ▲Shares held by funds +21.8%
- ▲Funds holding +7
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 79 | 72 | +9.7% |
| In funds' top 10 | 2 | 2 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 17 / 33 | 22 / 21 | +16.3% |
| Reduced / sold out | 14 / 9 | 19 / 7 | −11.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALVO is in one of them and how their past ALVO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALVO in an article yet. Here's the latest on the wider market.
About Alvotech
Alvotech is a biotechnology company based in Luxembourg that develops and manufactures biosimilars, which are lower cost versions of established biologic medicines. Its approved products copy treatments for conditions such as arthritis, psoriasis, Crohn's disease, macular degeneration and osteoporosis. The company handles research, manufacturing and regulatory work in-house and licenses its products to pharmaceutical partners that sell them in global markets, serving patients worldwide.
- Headquarters
- Luxembourg, Luxembourg



